
Andre R Jordan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/893204/publications.pdf Version: 2024-02-01



ANDRE P IORDAN

#	Article	IF	CITATIONS
1	The Role of CD44 in Disease Pathophysiology and Targeted Treatment. Frontiers in Immunology, 2015, 6, 182.	4.8	187
2	Targeting Hyaluronic Acid Family for Cancer Chemoprevention and Therapy. Advances in Cancer Research, 2014, 123, 35-65.	5.0	121
3	Dietary Supplement 4-Methylumbelliferone: An Effective Chemopreventive and Therapeutic Agent for Prostate Cancer. Journal of the National Cancer Institute, 2015, 107, .	6.3	69
4	Hyaluronic acid family in bladder cancer: potential prognostic biomarkers and therapeutic targets. British Journal of Cancer, 2017, 117, 1507-1517.	6.4	49
5	Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA. Journal of Urology, 2020, 203, 62-72.	0.4	33
6	Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer. Oncotarget, 2017, 8, 24262-24274.	1.8	20
7	A chemokine/chemokine receptor signature potentially predicts clinical outcome in colorectal cancer patients. Cancer Biomarkers, 2019, 26, 291-301.	1.7	17
8	A Novel Splice Variant of HYAL-4 Drives Malignant Transformation and Predicts Outcome in Patients with Bladder Cancer. Clinical Cancer Research, 2020, 26, 3455-3467.	7.0	13
9	Promotion of epithelial hyperplasia by interleukinâ€8—CXCR axis in human prostate. Prostate, 2020, 80, 938-949.	2.3	10
10	Molecular targeting of renal cell carcinoma by an oral combination. Oncogenesis, 2020, 9, 52.	4.9	8
11	HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in	7.0	8

Patients with Bladder Cancer. Clinical Cancer Research, 2021, 27, 4410-4421.